April 2026
The United States, in partnership with the Global Fund, has delivered lenacapavir, a cutting-edge new HIV prevention medication developed by U.S. company Gilead, to Uganda—marking a significant milestone in the global fight against HIV/AIDS.
Uganda is one of the ten priority countries selected for the initial rollout and the fifth in Africa to receive the product. The first shipments arrived on February 24, 2026, marking the launch of a new phase in HIV prevention under the U.S.–Uganda partnership. The introduction of lenacapavir reflects both American innovation and Ugandan leadership, advancing efforts to deliver effective, life-saving HIV prevention tools.
This groundbreaking medication has the potential to prevent nearly all new HIV infections. This effort underscores continued U.S. leadership in promoting innovation, strengthening self-reliance, and supporting durable health systems, in accordance with the Trump Administration’s America First Global Health Strategy.
The Government of Uganda, in close collaboration with the United States and other global partners, is leading the lenacapavir roll-out to Ugandan citizens.
Strategic Impact
The United States and The Global Fund, in partnership with Uganda’s Ministry of Health, will deliver enough doses of lenacapavir to treat 46,000 people in 2026, with plans to expand supply in 2027 and beyond. This initiative leverages U.S. innovation to advance shared goals to end
HIV as a public health threat by 2030, reduce new infections by 90 percent, and contribute to the elimination of mother-to-child transmission.
Demonstrating continued leadership in global health, the United States, alongside the Global Fund, is co-investing to expand access, including
procurement to reach up to 3 million people by 2028, with Gilead Sciences providing the medication at cost and supporting expanded generic production.
Why Lenacapavir Matters for Uganda
Lenacapavir, the long-action injectable developed by the American company Gilead Sciences, is one of the most significant advances in HIV prevention in decades.
Lenacapavir:• Demonstrated over 99% effectiveness in clinical trials
• Offers safe, discreet, and highly effective protection
• Requires twice-a-year administration, increasing cost-effectiveness and convenience and reducing the burden of daily pills or monthly injections
The introduction of lenacapavir in Uganda will significantly improve Ugandans’ access to HIV protection. Building on Uganda’s progress in the fight against HIV/AIDS and U.S. global health leadership, lenacapavir will play an important role in reducing the current rate of nearly 37,000 new HIV infections per year, , particularly among:
• Adolescent girls and young women
• Pregnant and breastfeeding mothers and their babies
• Other persons at high HIV risk
